Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

Fig. 2

Dichotomized comparison of levels of Aβ38, Aβ40 and Aβ42 and concentration ratios Aβ42/Aβ40, Aβ42/Aβ38 and Aβ38/Aβ40 in diluted IP eluates. No statistically significant differences in levels of a Aβ42, b Aβ40 and c Aβ38 between diagnostic groups. In contrast, significantly lower d Aβ42/Aβ40 (t test p < 0.001) and e Aβ42/Aβ38 (t test p = 0.0031) ratios observed in AD-D group compared to OD group. f Aβ38/Aβ40 ratio did not differ significantly between diagnostic groups (p = 0.0785). Statistical tests were done after log transformation. Accordingly, scaling of y axes is logarithmic. Aβ amyloid beta, AD-D dementia of the Alzheimer type, OD dementia due to other reasons

Back to article page